- Case Report
- Open Access
Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report
- Tsuyoshi Mashitani1,
- Hitoshi Yoshiji1Email author,
- Masaharu Yamazaki1,
- Yasuhide Ikenaka1,
- Ryuichi Noguchi1,
- Masatoshi Ishikawa1,
- Hideto Kawaratani1,
- Norihide Matsuo1,
- Masahito Uemura1,
- Junichi Yamao1,
- Masao Fujimoto1,
- Akira Mitoro1,
- Masahisa Toyohara1,
- Motoyuki Yoshida1,
- Masayoshi Sawai1,
- Chie Morioka1,
- Tatsuhiro Tsujimoto1,
- Mitsuteru Kitade1,
- Kosuke Kaji1,
- Yosuke Aihara1 and
- Hiroshi Fukui1
© Mashitani et al; licensee BioMed Central Ltd. 2009
- Received: 04 November 2008
- Accepted: 07 January 2009
- Published: 07 January 2009
Although several recent reports have shown that hepatocellular carcinoma (HCC) developed in patients with chronic hepatitis C (CH-C) even after having a sustained virological response (SVR) to interferon (IFN) therapy, it is not common for HCC to develop more than 10 years after SVR.
A 73-year-old Japanese man with CH-C who achieved SVR to IFN therapy 13 years ago was admitted into our hospital because of huge multiple liver tumors along with marked elevation of the tumor markers. Several diagnostic modalities strongly suggested HCC, and we performed histopathological examination. After confirming the diagnosis as well-differentiated HCC, we successfully treated these tumors with intensive combination therapies.
Our report highlights the need for careful follow-up for more than 10 years even if the patients with CH-C achieve SVR to IFN therapy.
- Sustained Virological Response
- Bile Duct Invasion
- Sustained Virological Response Patient
- Histological Fibrosis Stage
- Advanced Histological Stage
Hepatitis C virus (HCV) infection is the major cause of chronic liver diseases and death, not only in Japan but also throughout the world . Continuous inflammation associated with HCV induces hepatic fibrosis that can lead to liver cirrhosis and hepatocellular carcinoma (HCC). The goal of therapy for chronic hepatitis C (CH-C) is eradication of HCV. Recently, anti-viral therapy against HCV has been markedly improved, especially treatment with interferon (IFN) and anti-virus agents such as ribavirin . A sustained virological response (SVR), defined as seronegative polymerase chain reaction for HCV-RNA 6 months after cessation of therapy, has increased from around 5% with IFN monotherapy to almost 50% with the combination of pegylated-IFN (Peg-IFN) and ribavirin . IFN therapies for chronic hepatitis C, in general, have proved effective to improve hepatic inflammation, ameliorate fibrosis and may therefore reduce the risk of HCC . Furthermore, achievement of SVR after IFN therapy was reportedly associated with reduction of the liver-related mortality and the risks of complications and HCC development . However, several investigators have recently disclosed that HCC did develop even after achievement of SVR to IFN in patients with CH-C [6, 7]. In most of these reported cases, HCC development could be noticed within 5 years after SVR . The possible existence of a small and invisible HCC, which was undetectable by various imaging procedures at the time of IFN therapy, is considered responsible for the development of HCC after complete response to IFN [8, 9]. Therefore, it has been considered that HCC rarely develops long after HCV eradication. It is not common for HCC to develop more than 10 years after the achievement of SVR . It is well known that the risk of HCC increases with the degree of liver fibrosis, and that HCV-related HCC rarely develops in patients without advanced fibrosis [10, 11]. Similarly, among patients with SVR, advanced histological stage of disease has been linked with the development of HCC [6, 7]. We report herein a rare case of a patient with CH-C that developed 13 years after SVR associated with only mild liver fibrosis.
HCC is now one of the most common malignancies in the world with an estimated annual incidence of more than one million new cases per year, and HCV infection is now one of the predominant causes of HCC . The ultimate goal of therapy for CH-C is to prevent HCC and improve the long-term prognosis . IFN is widely used for eradication of HCV, and IFN therapy is known to lower the incidence of HCC, especially in patients who achieved SVR . However, recent studies revealed that the risk of developing HCC still exists even after SVR. Previous studies showed that HCC develops in 2.3–4.2% of patients of CH-C with SVR [6, 7]. Development of HCC after IFN therapy should be considered when the interval between SVR and detection of HCC is at least a couple of years to rule out the possibility of pre-existing latent microscopic tumors. Since most tumors of HCC that develop in patients with SVR were usually detected within 5 years, several investigators speculated that HCC was already present but too small to be detected at the time of completion of IFN therapy [8, 9]. This speculation is not the case in our patient, since SVR was achieved 13 years ago and no HCV-RNA could be detected when huge HCC appeared. Therefore, another possible mechanism should be considered.
Among the patients with SVR, the degree of liver fibrosis, advanced age, male sex, and alcohol intake, are higher serum alanine aminotransferase (ALT) levels are well-known risk factors for the development of HCC [6, 7]. Makiyama et al. showed that, in SVR patients, the risk ratio for developing HCC was more than seven times greater in patients over 55 years of age, and was more than twice as high in patients who had advanced histological stage of the disease . It has been reported that male sex is associated with a two- to three-times increased risk of HCC as compared with females . Also, recent reports have suggested that obesity and diabetes mellitus were associated with an increase risk of HCC development in patients with HCV-related cirrhosis . Our patient had no alcohol abuse, high ALT, or advanced fibrosis. Furthermore, the body mass index (BMI) of this patient is 21.5 and his fasting blood glucose was 85 mg/dl, both of them were within the normal ranges. Collectively, since only the age and sex were the only risk factors in our patient, it is not likely that these factors are the major reasons for huge HCC development 13 years after SVR.
Although the mechanism of HCC development in patients with SVR is still unclear, several studies have indicated that occult infection of hepatitis B virus (HBV) may be one of the carcinogenic factors . It is well known that integration of the HBV genome into the host DNA induces HCC development in HBV-related liver disease . Several investigators have shown that HBV DNA integration could be observed in some CH-C patients with SVR who developed HCC . Although occult infection of HBV was not examined, anti-hepatitis B core antibody (HBcAb) was positive in this patient. It may be possible that occult HBV infection developed in this patient and played some role in the HCC development 13 years after SVR. Further studies are required in the future to elucidate the possible mechanism involved.
In conclusion, the risk of HCC development in patients with CH-C and SVR cannot be underestimated. Especially if the patients had at least one of the risk factors, e.g., the advanced histological fibrosis stage, advanced age, male sex, alcohol intake, higher serum ALT, obesity, diabetes mellitus, and history of HBV infection, an annual follow-up with strict surveillance program for HCC should be performed for more than 10 years after the completion of IFN therapy.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Authors may also like to acknowledge (anonymously) the patient on whom the case report is based.
- Bosch FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 1999, 19: 271-285. 10.1055/s-2007-1007117.View ArticlePubMedGoogle Scholar
- McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339: 1485-1492. 10.1056/NEJM199811193392101.View ArticlePubMedGoogle Scholar
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002, 347: 975-982. 10.1056/NEJMoa020047.View ArticlePubMedGoogle Scholar
- Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999, 29: 1124-1130. 10.1002/hep.510290439.View ArticlePubMedGoogle Scholar
- Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y, Omata M: Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004, 53: 425-430. 10.1136/gut.2003.030353.View ArticlePubMedPubMed CentralGoogle Scholar
- Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004, 101: 1616-1622. 10.1002/cncr.20537.View ArticlePubMedGoogle Scholar
- Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S: Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007, 27: 186-191. 10.1111/j.1478-3231.2006.01406.x.View ArticlePubMedGoogle Scholar
- Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, Hayakawa T, Fukuda Y: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2001, 16: 1131-1137. 10.1046/j.1440-1746.2001.02595.x.View ArticlePubMedGoogle Scholar
- Suganami F, Tomiyama Y, Ohmoto K, Kawase T, Yoshioka N, Shibata N, Yoshida K, Kuboki M, Yamamoto S: [Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C]. Nippon Shokakibyo Gakkai Zasshi. 2007, 104: 809-814.PubMedGoogle Scholar
- Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000, 89: 53-59. 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998, 28: 930-938. 10.1016/S0168-8278(98)80339-5.View ArticlePubMedGoogle Scholar
- Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C: Which patients with hepatitis C develop liver complications?. Hepatology. 2000, 31: 513-520. 10.1002/hep.510310236.View ArticlePubMedGoogle Scholar
- Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005, 54: 533-539. 10.1136/gut.2004.052167.View ArticlePubMedPubMed CentralGoogle Scholar
- Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G: Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004, 126: 102-110. 10.1053/j.gastro.2003.10.048.View ArticlePubMedGoogle Scholar
- Tamori A, Nishiguchi S, Shiomi S, Hayashi T, Kobayashi S, Habu D, Takeda T, Seki S, Hirohashi K, Tanaka H, Kubo S: Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus. Am J Gastroenterol. 2005, 100: 1748-1753. 10.1111/j.1572-0241.2005.41914.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.